X

Trial Profile

A Phase 2, Open-label Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumor (TET) Progressing After Primary Chemotherapy (SELECT)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 04 Jul 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Selinexor (Primary)
Indications Thymic epithelial tumour; Thymoma
Focus Therapeutic Use
Acronyms SELECT

Most Recent Events

04 Jun 2024 Results of pooled analysis (NCT03193437 and NCT03466827 trials, n=31) assessing selinexor in patients with advanced thymoma and thymic carcinoma were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
18 Apr 2022 Status changed from active, no longer recruiting to discontinued.
11 Aug 2021 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com